AI companies have discovered a new frontier for their money, and it sits a few centimeters behind your forehead.
Coherence Neuro, a startup building a coin-sized implant that listens to tumors, has become part of a widening wave of AI-adjacent bets on brain data. The company’s disclosed backers, however, do not include OpenAI. The ChatGPT maker’s confirmed neurotech wager is a different company: Merge Labs, the brain-computer interface venture co-founded by Sam Altman.
A tumor monitor the size of a coin
Coherence was founded in 2022 and works on bioelectronic devices for monitoring and treating cancer. Its flagship system is called SOMA.
Tumors produce electrical signals, and SOMA is designed to pick them up. The same device can also deliver stimulation aimed at the tumor.
Early preclinical work in mouse models showed the approach could tell healthy brain tissue apart from tissue carrying a tumor.
In June 2026, Coherence tested a temporary version of the device in three patients at the Royal Melbourne Hospital. The implant was used during brain surgery, and the goal was to validate safety before longer human trials begin.
The company’s longer-term target is glioblastoma, one of the most aggressive forms of brain cancer. Coherence is aiming for its first chronic human implants in 2027.
Follow the money
Coherence closed a $10 million seed round disclosed in November 2025. The round was led by Artesian and Topology Ventures, with Blackbird among the participating investors.
Former Neuralink staff have consulted for Coherence, giving it a line into the Elon Musk-backed implant company’s hard-won experience with putting electronics inside skulls.
OpenAI’s neurotech money went elsewhere. The company participated in a $252 million seed round for Merge Labs, announced in January 2026. Merge Labs is pursuing ultrasound-based brain-computer interfaces that do not require an implant.
Why AI wants your brain data
Beyond Altman’s Merge Labs, Synchron, another brain-computer interface developer, has partnered with Nvidia. Neuralink remains the most visible player and, through its alumni, has fingerprints across the sector.
Coherence’s angle is narrower. It is not trying to decode language or let people type with their minds. It wants to track tumor activity and respond to it, a goal with a clear patient population and a well-understood regulatory path.
What this means for the neurotech race
Brain-computer interfaces are splitting into distinct lanes. The first is broad interface technology, represented by Merge Labs and Neuralink, attracting large rounds. The second is clinical, disease-specific devices like Coherence’s SOMA, where the addressable market is smaller but the use case is concrete.
Coherence’s three-patient test in Melbourne is the opening move in the regulatory process, not the finish line. The 2027 target for chronic implants is a goal, and medical timelines have a habit of drifting.
A device that continuously records electrical activity from inside the brain generates exactly the kind of information AI companies prize. How that data is stored, shared and potentially used to train models will become a bigger issue as these devices move from operating rooms into daily life.
Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.